Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 11/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 7/20 | 0.40 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.38 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.38 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | HTR2A | P28223 | 2/20 | 0.30 |
| ▸ | HTR2C | P28335 | 2/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27118151 | 1.00 | PTGS2 (0.40) | PTGS2PTGS1PDE7APDE3APDE10A | |
| SCHEMBL27118272 | 0.87 | PTGS2 (0.38) | PTGS2PTGS1PDE7APDE3APDE10A | |
| SCHEMBL30759516 | 0.86 | PTGS2 (0.42) | PTGS2PTGS1HTR2AHTR2CALDH1A1 | |
| SCHEMBL27118042 | 0.86 | PTGS2 (0.42) | PTGS2PTGS1HTR2AHTR2CALDH1A1 | |
| SCHEMBL27118935 | 0.85 | PDE7A (0.38) | PDE7APDE3APDE10ALMNAALDH1A1 | |
| SCHEMBL30759620 | 0.85 | PDE7A (0.40) | PDE7APDE3APDE10ALMNAALDH1A1 | |
| SCHEMBL30759622 | 0.85 | PDE7A (0.40) | PDE7APDE3APDE10ALMNAALDH1A1 | |
| SCHEMBL27119529 | 0.85 | PDE7A (0.40) | PDE7APDE3APDE10ALMNAALDH1A1 | |
| SCHEMBL30759559 | 0.83 | PTGS2 (0.35) | PTGS2PTGS1PDE7APDE3APDE10A | |
| SCHEMBL30759534 | 0.83 | PDE7A (0.35) | PTGS2PTGS1PDE7APDE3APDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260008783-A1 | MODULATORS OF FSHR AND USES THEREOF | GEDEON RICHTER PLC (HU) | 2026-01-08 | — | — | US | disclosed |
| EP-4577206-A2 | NOVEL MODULATORS OF FSHR AND USES THEREOF | Celmatix Inc. (US) | 2025-07-02 | — | — | EP | disclosed |
| WO-2024044778-A2 | NOVEL MODULATORS OF FSHR AND USES THEREOF | CELMATIX INC. (US) | 2024-02-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260008783-A1 | MODULATORS OF FSHR AND USES THEREOF | FSHR, GNRHR, LHCGR | PTGS2 2868/4885PTGS1 1711/4885PDE7A 400/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.